ATE344043T1 - Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung - Google Patents

Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung

Info

Publication number
ATE344043T1
ATE344043T1 AT99943916T AT99943916T ATE344043T1 AT E344043 T1 ATE344043 T1 AT E344043T1 AT 99943916 T AT99943916 T AT 99943916T AT 99943916 T AT99943916 T AT 99943916T AT E344043 T1 ATE344043 T1 AT E344043T1
Authority
AT
Austria
Prior art keywords
alpha
hypoxia
inducible factor
mutein
stable
Prior art date
Application number
AT99943916T
Other languages
English (en)
Inventor
Gregg L Semenza
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE344043T1 publication Critical patent/ATE344043T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT99943916T 1998-08-25 1999-08-25 Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung ATE344043T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/148,547 US6124131A (en) 1998-08-25 1998-08-25 Mutant hypoxia inducible factor-1 HIF-1

Publications (1)

Publication Number Publication Date
ATE344043T1 true ATE344043T1 (de) 2006-11-15

Family

ID=22526230

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99943916T ATE344043T1 (de) 1998-08-25 1999-08-25 Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung

Country Status (11)

Country Link
US (3) US6124131A (de)
EP (1) EP1107768B1 (de)
JP (1) JP2002523028A (de)
AT (1) ATE344043T1 (de)
AU (1) AU758627B2 (de)
CA (1) CA2340328C (de)
DE (1) DE69933877T2 (de)
IL (2) IL141494A0 (de)
NO (1) NO20010920L (de)
NZ (1) NZ510002A (de)
WO (1) WO2000010578A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504847A (en) * 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
JP2004536552A (ja) * 2000-08-07 2004-12-09 アンジオジェネティクス・スウェーデン・エイ・ビー フォン・ヒッペル・リンドウ腫瘍抑制タンパク質による低酸素誘導因子−１の条件付き調節のメカニズム
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
WO2002089854A1 (en) 2001-05-09 2002-11-14 Anges Mg, Inc. Gene transfer of angiogenic factor for skin disease
WO2002094862A2 (en) * 2001-05-23 2002-11-28 Angiogene Inc. Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
US6838430B2 (en) 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
CN102552262A (zh) * 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US7053046B2 (en) * 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
CN100469370C (zh) * 2002-12-06 2009-03-18 法布罗根股份有限公司 一种稳定HIFα的制剂在制备调节脂肪代谢的药物中的应用
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CN1921892A (zh) * 2003-10-17 2007-02-28 艾克蒂斯生物公司 用于治疗癌症的msp36的慢病毒载体传递
JP2007510734A (ja) * 2003-11-07 2007-04-26 ザ ヘンリー エム． ジャクソン ファウンデイション 低酸素誘導性遺伝子発現の活性化
CA2546649A1 (en) * 2003-11-26 2005-06-16 Entelos, Inc. Treatment of rheumatoid arthritis with hypoxia-inducible factor 1.alpha. antagonists
US20050137568A1 (en) * 2003-12-17 2005-06-23 Jones Donald K. Activatable bioactive implantable medical device and method of use
US7294123B2 (en) * 2003-12-17 2007-11-13 Corris Neurovascular, Inc. Activatable bioactive vascular occlusive device and method of use
WO2005065309A2 (en) * 2003-12-31 2005-07-21 Actis Biologics, Inc. Lentiviral vector delivery of native and mutated igfbp-3 for treatment of cancer
US7247159B2 (en) * 2004-04-08 2007-07-24 Cordis Neurovascular, Inc. Activatable bioactive vascular occlusive device
WO2006009843A2 (en) * 2004-06-18 2006-01-26 The Johns Hopkins University Negative regulation of hypoxia inducible factor 1 by os-9
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
US20090304650A1 (en) * 2005-05-11 2009-12-10 Scott Edward W Repair of the Bone Marrow Vasculature
ATE470439T1 (de) * 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
US20090215687A1 (en) 2005-10-21 2009-08-27 Cornell Research Foundation, Inc. Compounds for Enhancing Hypoxia Inducible Factor Activity and Methods of Use
EP2005753B1 (de) * 2006-03-30 2016-12-21 LG Electronics, Inc. Verfahren und vorrichtung zum decodieren/codieren eines multi-view videosignals
US7759306B2 (en) * 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
CA2658972C (en) 2006-07-31 2019-11-26 Vascular Biogenics Ltd. Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
CN105770910A (zh) 2006-10-03 2016-07-20 建新公司 肌萎缩性侧索硬化症和其它脊髓病症的基因治疗
KR100992526B1 (ko) * 2007-11-21 2010-11-05 한국과학기술연구원 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
WO2017027810A2 (en) * 2015-08-12 2017-02-16 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
WO2020146758A1 (en) 2019-01-10 2020-07-16 The General Hospital Corporation Methods to treat mitochondrial-associated dysfunctions or diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
NZ504847A (en) 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1

Also Published As

Publication number Publication date
WO2000010578A1 (en) 2000-03-02
NO20010920D0 (no) 2001-02-23
US6562799B1 (en) 2003-05-13
EP1107768A4 (de) 2004-12-29
US6124131A (en) 2000-09-26
EP1107768A1 (de) 2001-06-20
NO20010920L (no) 2001-04-23
AU5691499A (en) 2000-03-14
IL141494A (en) 2009-05-04
DE69933877T2 (de) 2007-06-21
JP2002523028A (ja) 2002-07-30
IL141494A0 (en) 2002-03-10
EP1107768B1 (de) 2006-11-02
NZ510002A (en) 2003-11-28
AU758627B2 (en) 2003-03-27
DE69933877D1 (de) 2006-12-14
CA2340328C (en) 2011-06-21
US20030176349A1 (en) 2003-09-18
CA2340328A1 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
ATE344043T1 (de) Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung
LV10180A (lv) Farmaceitiska kompozicija
ES2043890T3 (es) Nuevo uso medico.
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
HU9300541D0 (en) Ligand to receptor c-kit qnd method for its utilization
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
KR950701226A (ko) C-키트 수용체의 리간드 및 그의 사용방법
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
DE68926679D1 (de) Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
EE9900428A (et) Köhavastased ravimkoostised
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
ES2102393T3 (es) Complejos de acido quinolona carboxilico--ion metalico--acido.
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE68909267D1 (de) Medikament zur Behandlung von fibrotischer Störung und antifibrotische Verbindung.
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ES2169124T3 (es) Acido 4-aminomicofenolico 6-sustituido y derivados con actividad inmunosupresora.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE206056T1 (de) Therapeutisches agens für neutropenie
SU950354A1 (ru) Способ лечени синдрома зап стного канала
SU628926A1 (ru) Способ лечени пародонтоза
ATE218869T1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties